Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.47 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837654 | 1.00 | HTT (0.51) | HTTALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL3837657 | 1.00 | HTT (0.51) | HTTALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL31023808 | 0.88 | MGLL (0.55) | HTTALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL26199223 | 0.86 | ALDH1A1 (0.51) | HTTALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL28327837 | 0.86 | ALDH1A1 (0.51) | HTTALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL21399850 | 0.86 | ALDH1A1 (0.51) | HTTALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL8115616 | 0.86 | CYP2D6 (0.57) | HTTALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL3805489 | 0.86 | CYP2D6 (0.57) | HTTALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL16903907 | 0.84 | CYP3A4 (0.45) | HTTALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL28679081 | 0.84 | ALDH1A1 (0.49) | HTTALDH1A1MAPTNPC1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227469-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227469-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2012-07-24 | — | — | US | disclosed |
| WO-2012022487-A1 | SUBSTITUTED CYCLIC CARBOXAMIDE AND UREA DERIVATIVES AS LIGANDS OF THE VANILLOID RECEPTOR | Grünenthal GmbH (DE) | 2012-02-23 | — | — | WO | disclosed |
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | GRUENENTHAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | GRUENENTHAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | GRUENENTHAL GMBH (DE) | 2012-02-23 | — | — | US | disclosed |
| WO-2010081851-A1 | PIPERIDIN-4-YLPIPERAZINE COMPOUNDS FOR THE TREATMENT OF HCV INFECTION | GENOSCIENCE PHARMA (FR) | 2010-07-22 | — | — | WO | disclosed |
| WO-2010081851-A1 | PIPERIDIN-4-YLPIPERAZINE COMPOUNDS FOR THE TREATMENT OF HCV INFECTION | GENOSCIENCE PHARMA (FR) | 2010-07-22 | — | — | WO | disclosed |
| EP-1720868-B1 | PYRIMIDINE DERIVATIVES FOR USE AS VANILLOID RECEPTOR LIGANDS AND THEIR USE IN THE TREATMENT OF PAIN | AMGEN INC (US) | 2009-11-04 | — | — | EP | disclosed |
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | BALAN CHENERA | 2009-08-06 | — | — | US | disclosed |
| US-7534798-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7534798-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-05-19 | — | — | US | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511044-B2 | Vanilloid receptor ligands and their use in treatments | AMGEN INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1883632-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | Amgen Inc. (US) | 2008-02-06 | — | — | EP | disclosed |
| WO-2006116563-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20060241296-A1 | Acute, inflammatory or neuropathic pain and inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disorders, urinary incontinence, and psoriasis; e.g. 5-chloro-8-((6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol | AMGEN INC. | 2006-10-26 | — | — | US | disclosed |
| US-20050182067-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-18 | — | — | US | disclosed |
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | AMGEN, INC. | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176726-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV3, TRPV2 | HTT 2639/4885ALDH1A1 3231/4885MAPT 805/4885 |
| US-20090197879-A1 | VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS | TRPV1, TRPV2, TRPV3 | HTT 1669/4885ALDH1A1 3238/4885MAPT 755/4885 |
| US-20050182067-A1 | Vanilloid receptor ligands and their use in treatments | TRPV1, TRPV2, TRPV3 | HTT 1669/4885ALDH1A1 3238/4885MAPT 755/4885 |
| US-20120046301-A1 | Substituted Cyclic Carboxamide and Urea Derivatives as Ligands of the Vanilloid Receptor | TRPV1, CNR1, CNR2 | HTT 3857/4885ALDH1A1 2463/4885MAPT 2720/4885 |
| US-20060241296-A1 | Acute, inflammatory or neuropathic pain and inflammatory diseases such as asthma, rheumatoid arthritis, inflammatory bowel disorders, urinary incontinence, and psoriasis; e.g. 5-chloro-8-((6-(4-(trifluoromethyl)phenyl)pyrimidin-4-yl)amino)-1,2,3,4-tetrahydronaphthalen-2-ol | TRPV1, HRH2, TRPA1 | HTT 1504/4885ALDH1A1 1326/4885MAPT 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.